#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Diabetes and obesity / 2020 - 39

Treatment with biosimilar insulin glargine in clinical practice: case report

Czech version

Authors: Adriana Philippiová
Authors‘ workplace: DIADA, s. r. o, Bardejov
Published in: Diab Obez 2020; 20(39): 65
Category: Case studies

Labels
Diabetology Obesitology
Editorial
Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus
Concentrations of fT3 in child patients with obesity
Non-alcoholic fatty liver disease from the point of view of diabetologist
Diabetes mellitus and liver diseases
The benefit of insulin glargine 300 U/ml for specific groups of patients in the context of available data
Management of antidiabetic treatment in an elderly fragile patient with diabetes mellitus
Peroral antidiabetics and thyroid diseases
COVID-19: the topic of the day
Comparison of cardiovascular studies with GLP-1 receptor agonists and their implication for clinical practice
Therapy with SGLT2 inhibitors: case reports
Treatment with the new modified insulin glargine (Semglee) in a patient with type 1 diabetes mellitus: case report
A positive effect of intensification of the treatment with biosimilar insulin glargine on metabolic compensation: case report
Edukácia v diabetologickom edukačnom centre v Martine
Diabetology EDUCATION FORUM
Article was published in

Diabetes and obesity

Issue 39
2020 Issue 39
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#